[Anxiolytic efficacy and tolerance of tetrabamate in anxious patients abusing alcohol. Multicenter double-blind versus placebo study]. 1986

H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau

The anxiolytic efficacy of tetrabamate was evaluated in 68 out-patients presenting an anxiety state with alcohol abuse according to DSM III criteria. The study followed a double-blind placebo-controlled design with parallel groups and lasted for 21 days. Anxiety was evaluated by the Hamilton anxiety scale, Norris visual analog scales, and the Hopkins Symptom Check List, along with the investigator's assessment. Safety was evaluated in terms of somatic symptoms (CHESS 84) and the physician's overall evaluation. The anxiolytic activity of tetrabamate (three 300 mg tablets/day) was significantly greater than that of placebo from seventh day on. There were no statistically significant differences in safety profile between tetrabamate and placebo. Moreover, in the tetrabamate group the significantly greater improvement in the scores of somatic symptoms indicates that the compound caused no notable adverse effects and its activity on somatic complaints (psychopathologic and/or toxic).

UI MeSH Term Description Entries
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000437 Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) Alcohol Abuse,Alcoholic Intoxication, Chronic,Ethanol Abuse,Alcohol Addiction,Alcohol Dependence,Alcohol Use Disorder,Abuse, Alcohol,Abuse, Ethanol,Addiction, Alcohol,Alcohol Use Disorders,Chronic Alcoholic Intoxication,Dependence, Alcohol,Intoxication, Chronic Alcoholic,Use Disorders, Alcohol
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties
D001463 Barbiturates A class of chemicals derived from barbituric acid or thiobarbituric acid. Many of these are GABA MODULATORS used as HYPNOTICS AND SEDATIVES, as ANESTHETICS, or as ANTICONVULSANTS.

Related Publications

H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
September 1981, The Journal of clinical psychiatry,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
February 1999, Annales de cardiologie et d'angeiologie,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
February 1989, Clinical neuropharmacology,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
August 1989, Acta psychiatrica Scandinavica,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
October 1985, Medicina clinica,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
February 1993, Der Nervenarzt,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
December 1993, International angiology : a journal of the International Union of Angiology,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
November 1988, Scandinavian journal of gastroenterology,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
January 1987, L'Encephale,
H Lôo, and J D Guelfi, and R Malka, and S Brion, and M Cottin, and J Gailledreau, and A Raab, and M Salfati, and A Sarda, and M Godchau
January 1990, Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris,
Copied contents to your clipboard!